#Netherlands #Utrecht #blood collection #Vitestro #Aletta

Overview of Funding

Vitestro, a trailblazer in the realm of medical robotics, has announced a significant milestone in its journey of innovation by securing $70 million in an oversubscribed Series B financing round. This achievement emphasizes the confidence that leading healthcare investors have in the company's mission to transform diagnostic blood collection processes through automation.

Who Invested?

The funding round attracted a number of reputable investors, including the Labcorp Venture Fund, Mayo Clinic, Sutter Health, and several new financial backers such as InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht. Additionally, existing supporters like Invest-NL, EIC Fund, and Sonder Capital continued their backing, marking a strong vote of confidence in Vitestro's groundbreaking technology.

Purpose of the Funding

The influx of capital will be utilized to advance the next generation of Vitestro’s flagship product, the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). With this investment, the company aims to achieve a deeper integration of the Aletta® device within high-volume clinical workflows, which is essential for the scaling of operations.

As part of its strategic plan, the funding will also facilitate the U.S. FDA De Novo regulatory pathway for Aletta® and bolster its global commercial readiness. This includes ramping up manufacturing capabilities, expanding clinical operations, and developing necessary commercial infrastructures to prepare for broader market penetration, beginning in Europe before extending to the U.S. market.

Vision for the Future

Toon Overbeeke, CEO and co-founder of Vitestro, stated, "Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection." He emphasized that the company’s technology has evolved into a clinically validated solution, ready for broader adoption.

With billions of diagnostic blood collection procedures conducted annually worldwide, Vitestro positions itself at the forefront of innovation in one of the most frequently performed invasive medical procedures. The ability to refine and improve this essential clinical workflow is expected to have far-reaching implications for healthcare delivery.

Technology Behind the Aletta® Device

The Aletta® ARPD™ employs advanced technologies, including multimodal imaging, artificial intelligence, and robotics, to perform blood collections with unprecedented precision and reliability. This autonomous system not only identifies suitable veins but also guides needle insertion and collects blood samples consistently. By addressing staffing challenges and minimizing variability that often arises with manual procedures, Aletta® enhances patient experience and operational efficiency in high-volume outpatient settings.

Expert Comments

"The Labcorp Venture Fund recognizes the significant potential in automating essential diagnostic procedures to enhance consistency and patient care," said Megann Vaughn Watters, Head of Labcorp Venture Fund. This sentiment is echoed by Dr. Fred Moll, a seasoned figure in the medical field, who remarked on the potential of Vitestro’s technology to establish a new standard of care, similar to the evolution seen in robotic surgery.

Conclusion

As Vitestro prepares for the next phase of growth, the support from both new and existing investors underscores a collective belief in the transformative potential of autonomous robotic systems in healthcare. The journey towards redefining blood collection with Aletta® marks a significant step towards modernizing clinical workflows, ensuring higher standards of care, and improving patient outcomes on a global scale.

For more detailed information about Vitestro and its innovative technology, visit Vitestro's website.